The use of disease-specific signatures of microRNAs (miRNAs) in exosomes has become promising for clinical applications, either as biomarkers or direct...
Read More »Parsortix selected by the European consortium to validate blood-based biomarkers for cancer
ANGLE plc, the specialist medtech company, is pleased to announce that it has been formally selected for CANCER-ID, the European consortium to validate blood-based biomarkers for cancer. CANCER-ID is a European consortium funded by the Innovative Medicines Initiative (IMI), with ...
Read More »